Alejandro Yovine

Phase II Study of Ecteinascidin-743 in Advanced Pretreated Soft Tissue Sarcoma Patients

Alejandro Yovine, M. Riofrio, Jean‐Yves Blay et al. · Journal of Clinical Oncology · 2004 · 309 citations

Ecteinascidin-743: A Marine-Derived Compound in Advanced, Pretreated Sarcoma Patients—Preliminary Evidence of Activity

Suzette Delaloge, Alejandro Yovine, A. Taamma et al. · Journal of Clinical Oncology · 2001 · 167 citations

Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study

Amanda Psyrri, Jérôme Fayette, Kevin J. Harrington et al. · Annals of Oncology · 2022 · 133 citations · Full text

A phase II study of Yondelis® (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer

Laurent Zelek, Alejandro Yovine, Étienne Brain et al. · British Journal of Cancer · 2006 · 86 citations · Full text

Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: A phase I study in advanced gastrointestinal cancer patients

François Goldwasser, Marine Gross‐Goupil, Jean‐Marie Tigaud et al. · Annals of Oncology · 2000 · 53 citations · Full text

Dose Escalation, Gastrointestinal Oncology, Medicine +8